Companies › Nanjing IASO Biotechnology
4 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Aug 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Equecabtagene Autoleucel Injection CAR-T cell therapy targeting CD138 and/or BCMA | – | Phase 3 | Multiple Myeloma | Aug 2027 |
| UB-VV410 CD19-targeted CAR-T cell therapy | – | Phase 1 | Systemic Lupus Erythematosus | May 2028 |
| UB-VV400 Third-generation self-inactivating lentiviral vector encoding anti-CD19 CAR-T cells | – | Phase 1 | Large B-cell Lymphoma | May 2028 |
| CAR-GPRC5D (RD118) anti-GPRC5D CAR-T cell therapy | GPRC5D | Phase 1 | Relapsed/Refractory Multiple Myeloma | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05759793 | CAR-GPRC5D (RD118) | Phase 1 | Relapsed/Refractory Multiple Myeloma | Oncology | Sep 2025 |
| NCT06464991 | Equecabtagene Autoleucel Injection | Phase 3 | Multiple Myeloma | Oncology | Aug 2027 |
| NCT07109986 | UB-VV410 | Phase 1 | Systemic Lupus Erythematosus | Immunology | May 2028 |
| NCT06743503 | UB-VV400 | Phase 1 | Large B-cell Lymphoma | Oncology | May 2028 |
PharmaMar GI Innovation Nanjing Leads Biolabs Chipscreen Biosciences RayzeBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.